Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

116.98 +0.95 (+0.82%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,346,680
Open 116.00
Bid (Size) 116.13 (1)
Ask (Size) 117.27 (1)
Prev. Close 116.03
Today's Range 115.03 - 117.11
52wk Range 70.73 - 117.11
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
3 Drug Stocks With Promising Pipelines for 2023
These 3 drug stocks with promising pipelines are in position to reward investors in 2023 due to multiple factors. 
Via InvestorPlace
Cramer Is Holding This Biotech Stock
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended holding Biomarin Pharmaceutical Inc (NASDAQ: BMRN). 
Via Benzinga

Performance

YTD
+16.27%
+16.27%
1 Month
+14.51%
+14.51%
3 Month
+36.45%
+36.45%
6 Month
+34.34%
+34.34%
1 Year
+39.76%
+39.76%

More News

Read More
Vertex Pharmaceuticals Stock Sees Rising Relative Strength
Via Investor's Business Daily
BioMarin's Growth Prospects Soar with Potential Voxzogo and Roctavian Launches, Analyst Raises Price Target
Via Benzinga
6 Analysts Have This to Say About Biomarin Pharmaceutical
Via Benzinga
2 Top Biotech Stocks Defying the Bear Market
Via The Motley Fool
Top Picks For 2023: Catalyst Pharmaceuticals
Via Talk Markets
Expert Ratings for Biomarin Pharmaceutical
Via Benzinga
Expert Ratings for Biomarin Pharmaceutical
Via Benzinga
Why BioMarin Pharmaceuticals Fell 6.9% on Thursday
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Canceled AdCom, UniQure's Hemgenix Approval Show Positive Signs For BioMarin's Hemophilia Candidate
Via Benzinga
Expert Ratings for Biomarin Pharmaceutical
Via Benzinga
One Rejected BioMarin's Hemophilia Gene Therapy Goes Under FDA Review
Via Benzinga
BioMarin Lays Off 4% Of Its Workforce To 'Simplify' The Company
Via Benzinga
The FDA Just Approved The Most Expensive Drug Ever — Sending UniQure Stock On A Warpath
Via Investor's Business Daily
Why Biomarin Pharmaceutical Stock Hit A New 52-Week High Today
Via Benzinga
$1.4 Million Bet On This Real Estate Stock? 3 Stocks Insiders Are Buying
Via Benzinga
10 Analysts Have This to Say About Biomarin Pharmaceutical
Via Benzinga
Mastercard To $428? Plus This Analyst Slashes PT On Intel
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
Via Benzinga
Biomarin Pharmaceutical: Q3 Earnings Insights
Via Benzinga
Recap: Biomarin Pharmaceutical Q3 Earnings
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.